← Back to Search

Other

VQW-765 for Performance Anxiety

Phase 2
Waitlist Available
Research Sponsored by Vanda Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ability and willingness to provide written informed consent.
Sufficiently fluent in English to participate in the trial.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights

Study Summary

This trial will compare the effects of VQW-765 to a placebo in people with performance anxiety. The trial is double-blind, meaning that neither the participants nor the researchers will know who is receiving the active drug or the placebo.

Eligible Conditions
  • Performance Anxiety

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Subjective Units of Distress Scale (SUDS)
Secondary outcome measures
Assessment of safety and tolerability of a single dose of VQW-765, as measured by spontaneous reporting of adverse events (AEs)
Clinician Global Impression of Change (CGI-C) scale at visit 2
Patient Global Impression of Change (PGI-C) scale at visit 2

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: VQW-765Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Vanda PharmaceuticalsLead Sponsor
60 Previous Clinical Trials
24,128 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~54 spots leftby Mar 2025